Novelix Pharmaceuticals Ltd Valuation

536565 · Retail · Current price

Full stock page
DocStoX fair value
Not published yet
No estimate for 536565 at this time
Current price
—
P/E ratio
78.5x
P/B ratio
3.1x
Model it yourself — Earnings Yield Calculator
Opens pre-filled with Novelix Pharmaceuticals Ltd's latest numbers.

Is Novelix Pharmaceuticals Ltd undervalued?

We have not published a fair value estimate for Novelix Pharmaceuticals Ltd yet. Our valuation engine covers the market in waves, and this company has not been through a run that met our publishing bar. Rather than show a second, inconsistent number here, we would rather show none. The ratios, peer comparison and methodology below are still based on Novelix Pharmaceuticals Ltd's reported financials.

Valuation multiples

Novelix Pharmaceuticals Ltd trades at a P/E of 78.5x and a P/B of 3.1x, with a dividend yield of 0.0%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.

How we estimate fair value

When we publish an estimate for Novelix Pharmaceuticals Ltd, it will appear here with the full working: the models used and their weights, every assumption and its source, the confidence band, and what data was missing. That is the same methodology we apply to every company.

Read the full fair-value methodology

Understand the ratios

P/E RatioP/B RatioPEG RatioEarnings Yield

More on Novelix Pharmaceuticals Ltd

Fair ValueIntrinsic ValueDCFFinancial RatiosPeers

DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.